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CASE REPORT
Dapsone Hypersensitivity Syndrome That Occurred 
during Treatment of Pediatric Patient with Erythema 
Elevatum Diutinum
Gun-Wook Kim, M.D., Hyun-Je Park, M.D., Hoon-Soo Kim, M.D., Su-Han Kim, M.D., 
Hyun-Chang Ko, M.D., Byung-Soo Kim, M.D., Ph.D., Moon-Bum Kim, M.D., Ph.D.
Department of Dermatology, Pusan National University School of Medicine, and Biomedical Research Institutue, Pusan National 
University Hospital, Busan, Korea
Herein, we report a case of an 8-year-old girl with dapsone 
hypersensitivity syndrome (DHS) that occurred during the 
treatment of erythema elevatum diutinum. She had fever, 
gross hematuria, and malaise for three weeks after initiation 
of dapsone therapy. Five days after stopping dapsone 
treatment, she returned to the emergency clinic because of 
high fever, emesis, diarrhea, upper respiratory symptoms, 
and worsening of exanthematous eruptions.  A diagnosis of 
DHS was made, and it improved with oral prednisone. We 
recommend that pediatric patients who are treated with 
dapsone need to be observed carefully for the development 
of DHS. (Ann Dermatol 23(S3) S290∼S295, 2011)
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INTRODUCTION
Dapsone is indicated for the treatment of leprosy, but it is 
also used for various skin diseases
1. Moreover, dapsone is 
the drug of choice for the management of erythema ele-
vatum diutinum (EED)
2. The most frequent associated side 
effects are dose-related hemolytic anemia and methaemo-
globinemia
2. More rarely, dapsone can cause severe ad-
verse effects, such as dapsone hypersensitivity syndrome 
(DHS) or agranulocytosis
1. DHS typically starts within ei-
ght weeks of initiating dapsone treatments and is charac-
terized by fever, rash, hemolytic anemia, lymphocytosis 
and hepatitis
1,3. Herein, we report DHS that occurred dur-
ing the treatment of a pediatric patient with EED.
CASE REPORT
An 8-year-old girl presented with tender papules and 
nodules on the extensor surfaces of the extremities that 
had been there for seven months. A physical examination 
revealed firm, erythematous to skin-colored papules and 
nodules on her both hands, wrist, feet, elbows, and knees 
(Fig. 1). The histopathologic examinations of the skin 
lesions from her hand revealed widespread vasculitis in 
the small vessels of the dermis with fibrinoid deposits and 
extravasated red blood cells. The infiltrates were com-
posed of multiple small aggregates of histiocytes, neu-
trophils, and nuclear fragments (Fig. 2). Thus, the clinical 
and histopathological findings were consistent with a diag-
nosis of EED.
Despite several months of potent topical and systemic 
steroid therapy, the cutaneous lesions remained, and she 
was started on dapsone treatment. The dosing regimen of 
dapsone consisted of taking 100 mg daily for two days 
and skipping for one day. A dramatic and rapid response 
was seen within two weeks of initiation of dapsone the-
rapy.Dapsone Hypersensitivity Syndrome in Patients with Erythema Elevatum Diutinum
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Fig. 1. (A) Multiple, persistent, sym-
metric and erythematous to skin- 
colored papules and nodules on the 
extensor surfaces of the hands. (B) 
Close up view of the right hand, (C)
right wrist, (D) right foot, (E) elbows
and (F) knees. 
Fig. 2. (A) Biopsy of an early lesion from the hand revealed widespread vasculitis in the small vessels of the dermis with fibrinoid
deposits and extravasated red blood cells (H&E, ×100).  (B) The infiltrates were composed of multiple small aggregates of histiocytes,
neutrophils, and nuclear fragments (H&E, ×400). 
However, she stopped the dapsone treatment after three 
weeks of treatment due to gross hematuria, malaise, fever, 
and cough. At that time, she was thought to have a viral 
illness or an unrelated upper respiratory infection. Never-
theless, five days after stopping treatment of dapsone, she 
returned to the emergency clinic because of high fever, 
emesis, diarrhea, upper respiratory symptoms, and a wor-
sening rash. She also had maculopapular exanthematous 
eruptions with facial edema and lymphadenopathies (Fig. 
3). She was hospitalized, and blood samples were taken 
for routine examination, including viral serology, bacterial 
culture, complement levels, and autoimmune screening.
A complete blood count revealed a hemoglobin of 9.7 
mg/dl, a hematocrit of 31.0, a white blood cell count of 
30,110/mm
3, reticulocyte count of 5.74%, a platelet count 
of 124,000/mm
3, and a C-reactive protein of 0.51 mg/dl in 
the first hour. Her liver function tests were abnormal: as-
partate aminotransferase 441 U/L, alanine aminotransfe-
rase 657 U/L, alkaline phosphatase 1,023 U/L, total bili-
rubin 6.06 mg/L, direct bilirubin 3.88 mg/dl, prothrombin 
time 16.2 seconds, international normalized ratio 1.35, 
partial thromboplastin time 43.0 seconds, and lactate 
dehydrogenase 2,221 U/L. Titers were negative for viral 
hepatitis serology (hepatitis A, B, and C) and Epstein-Barr GW Kim, et al
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Fig. 3. Symmetrically arranged, bri-
ghtly erythematous macules and 
papules on trunk (A), arms (B), legs
(C) and face with edematous swel-
ling (D).
virus. Although there was gross hematuria, the levels for 
urea, creatinine, and electrolyte in the blood were within 
normal limits. Bacterial cultures (blood and urine), levels 
of complement (C3, C4, and CH50), and autoimmune 
screen (antinuclear antibody) were all negative or within 
normal limits.
A diagnosis of DHS was made, and the patient was treated 
with oral prednisone (60 mg/day). Her condition impro-
ved quickly and laboratory test results returned to normal 
levels within two weeks.
DISCUSSION
EED is a chronic recurrent form of cutaneous leukocy-
toclastic vasculitis thought to be immune-complex me-
diated
4,5. It typically presents as multiple, persistent, sym-
metric and erythematous to violaceous papules/plaques 
on the extensor surfaces of the extremities
4,5. The histo-
pathologic features characteristic of EED are not usually all 
present within the same lesion
5. A spectrum from leuko-
cytoclastic vasculitis to vessel occlusion and dermal fib-
rosis are observed
5. Early stage lesions are characterized 
by neutrophilic, perivascular infiltrates with dermal fibrin 
deposits, endothelial expansion, and leukocytoclasis
5,6. 
With disease progression, a granulation tissue-like respon-
se with dermal fibrosis and capillary proliferation become 
the predominant features
5,6. Diagnosis of EED must be 
based on a characteristic clinical presentation and con-
firmatory histopathological findings
5,6.
Dapsone has been broadly used for treatment of leprosy 
and a wide variety of dermatological inflammatory disea-
ses because of its excellent anti-inflammatory and immu-
nomodulatory effects
1. Generally, dapsone or sulfonami-
des are considered to be a first-line treatment for EED
5,6. 
The responsiveness of EED to dapsone is thought to be 
secondary to its inhibitory effects on neutrophil chemo-
taxis and function
2. Therefore, we tried dapsone therapy 
in our patient, because her lesions did not respond to 
topical and systemic steroids. Although a dramatic and 
rapid response was seen within two weeks of initiation of 
therapy, DHS occurred three weeks after initiation of 
dapsone therapy.
The most frequent side effects of dapsones are dose- 
related methemoglobinemia and hemolytic anemia, and 
rarely, it can cause an idiosyncratic reaction, called dap-
sone hypersensitivity syndrome
1-3. DHS has been reported 
for a variety of dermatological conditions, including le-
prosy, dermatitis herpetiformis, acne vulgaris, psoriasis, le-
ukocytoclastic vasculitis, cicatrical pemphigoid, pem-
phigus and lupus erythematosus
1,3.  
A  true diagnosis of DHS should be made based on the 
following criteria: 1) symptoms manifesting within eight 
weeks of starting therapy and resolving after withdrawal of 
the drug, 2) symptoms not attributable to any other drug 
used simultaneously, and 3) symptoms unrelated to lep-
rosy or any underlying disease
7,8.
DHS is a severe, multiorgan reaction to dapsone that 
includes fever, rash, jaundice, lymphadenopathy, spleno-
megaly and pedal edema
1,3. Hemolytic anemia, atypical 
lymphocytosis and hepatitis are other accompanying find-
ings
1,3. Of note, fever almost invariably presents as the 
initial sign
9. In addition, prominent edema of the face, Dapsone Hypersensitivity Syndrome in Patients with Erythema Elevatum Diutinum
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Table 1. Reported cases of dapsone hypersensitivity syndrome in the Korean literature
Case number 1 2 3 4 5 6 7
Author Choi et al.
18 Kim and Kim
19 Kim and Kim
19 Lim et al.
20 Won et al.
21 Lee et al.
22 Our case
Age (yrs)/Gender 62/F 23/M 52/M 59/F 13/F 47/F 8/F
Primary disease Arthralgia Hand eczema Rheumatoid 
arthritis
Recurrent oral 
ulcer
Chronic skin 
disease
Behcet disease Erythema 
elevatum 
diutinum
Dose of dapsone  
 (mg/day)
100 100 100 50∼100 100 100 67
Duration of       
 therapy before   
 DHS (weeks)
  4   2   3 6   4   3  3
Fever − ＋＋＋＋＋＋
Rash Maculopapules Maculopapules, 
pustules
Maculopapules Maculopapules Maculopapules Maculopapules Maculopapules
Lymphadenopathy − ＋＋＋− ＋＋
White blood cells 
 (normal: 
  ＜11,000/mm
3)
8,740 13,300 15,000 21,500 13,110 10,100 31,110
Total eosinophils 
 (normal: 
  ＜600/mm
3)
  8.1% 7% 9% 3%     2.5%  15.2% 3.5%
Hemoglobin      
 (normal male:   
  ＞12.3; female:  
  ＞11.3 g/dl)
9.9 None None 7.4   8.0 7.7 9.7
C-reactive protein 
 (normal: ＜0.8   
 mg/dl)
None 2.53 2.24 None − 107  0.51
Albumin (normal:  
  ＞3.5 g/dl)
3.5 None None 2.1    3.11  2.6 3.5
Total bilirubin
 (normal: ＞1.2   
 mg/dl)
0.8 1.4 None 16.07    6.77 13.2  6.06
A s p a r t a t e          
 aminotransferase  
 (normal: ＜37   
 U/L)
88 1,996 567 561 182.4 3,224 441
A l k a l i n e           
 aminotransferase  
 (normal: ＜41   
 U/L)
84 3,416 345 608 334 2,703 657
A l k a l i n e           
 phosphatase     
 (normal: ＜220  
 U/L)
240 290 340 287 423.5 534 1,023
Systemic therapy Systemic 
steroids
Systemic 
steroids, 
antihistamines
Systemic 
steroids, 
antihistamines
Systemic 
steroids, 
immuno-
globulins
Systemic 
steroids
Systemic 
steroids
Systemic 
steroids
F: female, M: male, DHS: dapsone hypersensitivity syndrome.
particularly in the periorbital area, is a noticeable feature 
of drug induced hypersensitivity syndrome
9. The rash, 
which is often initially a benign morbilliform eruption, 
may develop into exfoliative dermatitis
1,3.  
Our patient showed consistent clinical and laboratory 
findings of DHS and her symptoms appeared within three 
weeks of starting on dapsone. In particular, it is note-
worthy that hemolytic anemia was also present, as proved 
by decreased hemoglobin, high reticulocyte count, and 
high bilirubin. In addition, it is essential to check levels of 
enzyme glucose 6-phosphate hydrogenase (G6PD) before 
beginning dapsone, because G6PD-deficient patients may GW Kim, et al
S294 Ann Dermatol
experience severe hemolysis
1-3.
It is presumed in the pathogenesis of DHS that hyper-
sensitivity to dapsone may be caused by metabolites of 
dapsone-forming haptens with the formation of anti- 
dapsone antibodies
10,11. The exact incidence of DHS is not 
known, but it is reported to occur in less than 1% of 
patients treated with dapsone
1,3. According to a study by 
Agrawal and Agarwalla
3, the mean age in patients with 
DHS was 33.2 years (range 13 to 64 years). Although 
aging was a relatively adverse predisposing factor for side 
effects of daponse
1, there was no higher predominance of 
DHS in pediatric patients. Most of the patients were below 
50 years of age and this may be because of the decreased 
enzyme activity and production of toxic metabolites with 
aging
1.
Typically the symptoms of DHS begin within two to six 
weeks of the start of therapy (Table 1). However, it can 
appear as early as six hours in a previously sensitized 
individual or as late as six months after the start of dap-
sone therapy
12. Due to its significant enterohepatic cir-
culation, dapsone has a long elimination half-life that 
averages between 24 and 30 hours
13. This is important to 
remember in case adverse reactions emerge after a long 
metabolite impact period
14. The initial dosage is crucial in 
DHS, and Labandeira and Toribio
15 suggest that a high 
dose (＞50 mg/day) in the first six to eight weeks of 
treatment is advisable in patients who do not have 
leprosy. A mortality rate of 11∼13% has been reported, 
and hepatic encephalopathy is prominent in fatal cases
16.
DHS is generally a self-limiting drug reaction, and most 
patients recover following cessation of dapsone therapy
14. 
However, a systemic corticosteroid is frequently used in 
its treatment. The duration of recovery has been shown to 
be shorter in patients who received a systemic cortico-
steroid, although no controlled studies have been per-
formed to evaluate it effectiveness
1,3. 
To our knowledge, there has been one reported case of 
DHS occurring in patients with EED. Potter et al.
17 repor-
ted the case of a 68-year-old man with EED who had been 
taking dapsone, 200 mg/day, and developed DHS three 
weeks after commencement of the drug. In fact, it is 
unclear whether EED itself affects DHS, because this case 
is the second case of DHS during treatment of EED. 
However, the use of dapsone is recently decreasing in 
dermatologic inflammatory disease because of the 
reduction of leprosy patients and development of new 
drugs. Moreover, it is difficult to find any dermatologic 
diseases for which dapsone is recommended as first line 
treatment. In this regard, it is highly suggestive that dap-
sone or sulfonamides are still considered a first-line treat-
ment for EED. Since treatment of EED remains challenging 
due to the chronic and recurrent nature of the disease, 
dapsone was necessary to use in our patient for the treat-
ment of EED.
In conclusion, we emphasize that more attention is 
needed for dapsone therapy in the patient with EED. In 
addition, physicians, especially those prescribing drugs for 
pediatric patients, should be alert to this rare but po-
tentially life-threatening adverse drug effect.
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